NCT05022849View on ClinicalTrials.gov

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

October 30, 2037

Study Completion Date

October 30, 2037

Conditions
Prostatic Neoplasms
Interventions
DRUG

JNJ-75229414

JNJ-75229414 infusion will be administered intravenously.

DRUG

Bridging Therapy

Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.

Trial Locations (8)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Medical Center, New York

19104

University of Pennsylvania, Philadelphia

28204

Levine Cancer Institute, Charlotte

40207

Norton Cancer Institute, Louisville

55455

University Of Minnesota, Minneapolis

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

91010

City of Hope Cancer Center, Duarte

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY